A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Study Identifier
P19-620
CT.gov Identifier
NCT04214028
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    12 - 17 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Chronic Hepatitis C Virus (HCV) infection treated in daily practice with Maviret * Enrolled after Maviret treatment begins * Prior treatment with Maviret
    Exclusion Criteria:
    None

    Protocol Summary

    This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.

    Study Locations

    Location
    Status
    Location
    Kariya Toyota General Hospital /ID# 239046
    Kariya-shi, Aichi-ken, Japan, 448-8505
    Status
    Not applicable
    Location
    Meijo Hospital /ID# 250955
    Nagoya, Aichi-ken, Japan, 460-0001
    Status
    Not applicable
    Location
    Nagoya University Hospital /ID# 226746
    Nagoya, Aichi-ken, Japan, 466-8560
    Status
    Not applicable
    Location
    Nagoya City University Hospital /ID# 238745
    Nagoya, Aichi-ken, Japan, 467-8602
    Status
    Not applicable
    Location
    Hirosaki University Hospital /ID# 262654
    Hirosaki-shi, Aomori, Japan, 036-8203
    Status
    Not applicable
    Location
    Misawa Municipal Misawa Hospital /ID# 229544
    Misawa-shi, Aomori, Japan, 033-0123
    Status
    Not applicable
    Showing {first} - {last} of {total} Results